title: The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain.
abstract: This test cultivated three groups of acute promyelocytic leukemia (APL) and NB4 cells in liquid in vitro, processed them with arsenic trioxide (ATO), daunorubicin (DNR), ATO+DNR respectively, and then set up blank control group. Apoptosis of cells in each group was observed using flow cytometry, procoagulant activity of APL and NB4 cells in each group was detected with recalcification time, and expressions of tissue factor (TF), thrombomodulin and annexin II of NB4 cells in each group were measured using ELISA method. The results showed that the apoptosis rate increased 4-8 times compared with blank control group after processing APL and NB4 cells with ATO and DNR; procoagulant activity decreased obviously; and expression of TF and annexin II of NB4 cells reduced significantly (P<0.05). We concluded that combination of ATO and DNR could promote APL and NB4 cell apoptosis effectively without aggravating blood coagulation disorders, which might improve coagulation function of APL by inhibiting coagulation and hyperfibrinolysis through reducing expression of TF and annexin II. This drug combination may be a safe and effective method in the treatment of APL of primary high white blood cells type.
authors.affiliation: Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
authors.forename: Na
authors.initials: N
authors.lastname: Qin
authors.affiliation: Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
authors.forename: Xinghua
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Hematology, the People's Hospital of Zhengzhou, Zhengzhou, Henan, China.
authors.forename: Shuxia
authors.initials: S
authors.lastname: Guo
mesh_terms: D000328:Adult; D017306:Annexin A2 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D045744:Cell Line, Tumor; D003630:Daunorubicin / Q000494:pharmacology; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000494:pharmacology; D018180:Thrombomodulin / Q000378:metabolism; D013925:Thromboplastin / Q000378:metabolism; D013997:Time Factors; D014407:Tumor Cells, Cultured; D055815:Young Adult
chemical_list: C472822:ANXA2 protein, human; D017306:Annexin A2; D001152:Arsenicals; D010087:Oxides; C546931:THBD protein, human; D018180:Thrombomodulin; D013925:Thromboplastin; D000077237:Arsenic Trioxide; D003630:Daunorubicin